Evaluating Guanfacine Hydrochloride in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adult Patients: Design, Development and Place in Therapy
Toyosaku Ota,Kazuhiko Yamamuro,Kosuke Okazaki,Toshifumi Kishimoto
DOI: https://doi.org/10.2147/DDDT.S221126
2021-05-12
Abstract:Toyosaku Ota, 1, 2 Kazuhiko Yamamuro, 1 Kosuke Okazaki, 1 Toshifumi Kishimoto 1 1 Department of Psychiatry, Nara Medical University, Kashihara, Japan; 2 Faculty of Nursing, School of Medicine, Nara Medical University, Kashihara, Japan Correspondence: Toyosaku Ota Department of Psychiatry, Nara Medical University, 840 Shijyo-Cho, Kashihara, Nara, 634-8522, Japan Tel +81-742-22-3051 Fax +81-742-22-3854 Email Attention-deficit/hyperactivity disorder (ADHD) is characterized by age-inappropriate and impairing levels of inattention, hyperactivity, or impulsivity, or a combination of these characteristics. It is estimated to affect around 4% of adults worldwide. In the past few decades, prescriptions for ADHD drugs (psychostimulants and non-psychostimulants) have increased significantly. However, the efficacy and safety of adult ADHD medications remains controversial. Guanfacine extended-release (GXR) is a non-psychostimulant ADHD drug that is a selective α 2A-adrenergic receptor agonist, first approved for treatment of adult ADHD in Japan in June 2019. Our aim was to provide an overview of GXR pharmacology and review the studies on efficacy and safety that have been conducted in adults with ADHD. The beneficial actions of guanfacine are thought to be attributed to the strengthening of prefrontal cortical network connections, which regulate attention, emotion, and behavior via the activity at post-synaptic α 2A receptors. Current evidence of GXR efficacy and safety suggests that GXR is an effective monotherapy treatment option for adults with ADHD. Keywords: attention-deficit/hyperactivity disorder, pharmacotherapy, guanfacine, adults, nonstimulant Attention-deficit/hyperactivity disorder (ADHD) is characterized by age-inappropriate and impairing levels of inattention, hyperactivity, or impulsivity, or a combination of these characteristics. 1 It is estimated to affect 7–10% of children 2 and about 4% of adults. 3 Available pharmacological treatments for ADHD include psychostimulant (eg methylphenidate and amphetamine) and non-psychostimulant medications (eg atomoxetine and α2-agonists). In the past few decades, prescriptions for ADHD drugs have significantly increased globally. 4 , 5 Despite clinical guidelines recommending the use of these drugs for treating ADHD, 6–9 the treatment guidelines for adult ADHD are developing. Guanfacine extended-release (GXR) is a nonstimulant, selective, α2A-adrenergic receptor agonist. The guanfacine extended-release formulation has been available in the United States since 2009. The GXR is approved by the US Food and Drug Administration for the treatment of ADHD in patients aged 6–17 years, either as monotherapy or an adjunctive therapy for stimulants. However, there have not been sufficient examinations of efficacy and safety of this drug in adults with ADHD. In fact, GXR for adults was not included in the comprehensive 2018 systematic review and meta-analysis of medications for ADHD; 10 moreover, it has not been included in the current international guidelines. 11 In Japan, GXR was first approved for treatment of adults with ADHD in June 2019. Therefore, we sought to provide an overview of GXR pharmacology and review studies that have evaluated the efficacy and safety of GXR for the treatment of adults with ADHD. Guanfacine differs from clonidine in that it is a phenylacetylguanidine derivative 12 and is more selective in its α2 agonism. 13 Like the action of clonidine, it lowers blood pressure by activating brainstem receptors, which leads to decreased sympathetic tone. 14 Guanfacine's beneficial effects on ADHD are thought to occur via its agonism at α2A-adrenoceptors in the prefrontal cortex. The prefrontal cortex is the primary brain area implicated in ADHD, and the prefrontal dysfunction may underlie symptoms of inattentiveness, impulsivity, and excessive motor activity. 15 Furthermore, the prefrontal cortex is important for executive functions (eg planning, decision making, judgment, and response inhibition). Both norepinephrine and dopamine are crucial for prefrontal cortex functions. 16 Sufficient levels of norepinephrine are required for optimal working memory and attention; however, excessive norepinephrine release (eg during stress) can also impair cognitive functions. 15 Optimal levels of norepinephrine ac -Abstract Truncated-